Dialog Box


Live Q&A: Access to Medicines with Prof. Andrew Wilson

21 May 2018 at 12:00 AM

Rare Cancers Australia hosted our latest Facebook Live Q&A on May 15, 2018, with Professor Andrew Wilson, Chair of the Pharmaceutical Benefits Advisory Committee (PBAC) which oversees the Pharmaceutical Benefits Scheme (PBS) in Australia.

Unfortunately due to technical issues beyond our control the video feed was lost. Presented here is the original introduction followed by the full audio recording of that conversation.

Questions, Timestamps and Transcript
  • Introduction (0:00)
  • Question 1 – How do the TGA, PBAC and PBS work and how are drugs approved? (0:45)
  • Question 2 – How does the PBAC deal with lack of data for rare cancers? (7:46)
  • Question 3 – Does  the PBAC consider the cost of not funding a drug? (9:17)
  • Information – On questions about specific drugs / conditions (11:28)
  • Question 4 – How does information from other countries inform the process and what affects priority in the approvals process? (12:45)
  • Question 5 – What can be done for drugs for multiple uses? (16:56)
  • Question 6 – What is the potential for provisional listings? (22:04)
  • Question 7 – What is the best way for the public to assist the process? (25:54)
  • Question 8 – What gives you the most hope? (30:44)
  • Conclusion (33:18)

A full transcript is available here.

Like the Rare Cancers Australia Facebook Page so you don't miss our next Live Q&A.

Category: Rare Cancers in the News
Tags: Andrew Wilson, answers, cancer, Facebook Live, PBAC, PBS, Pharmaceutical Benefits Advisory Committee, Pharmaceutical Benefits Scheme, Professor, q&a, questions, rare cancer, Rare Cancers Australia, RCA, TGA,